Business Wire·Dec 3, 2025, 4:01 PM ET

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Delcath Systems, Inc. announced the publication of a 10-year retrospective study in the journal Cancers regarding percutaneous hepatic perfusion (PHP) for liver-dominant metastatic uveal melanoma.
The study analyzed 38 consecutive patients who underwent 99 procedures using Delcath's CHEMOSAT Hepatic Delivery System for Melphalan at Asklepios Hospital Barmbek in Hamburg, Germany.
The research reports a median overall survival (OS) of 29.1 months from the first PHP treatment, with 1-, 2-, and 3-year OS rates of 79.5%, 53.2%, and 28.5% respectively.
Patients receiving three or more PHP cycles demonstrated a numerically improved median OS of 29.8 months compared to 21.4 months for those receiving two or fewer cycles, with each additional cycle associated with a ~40% reduction in the risk of death.
No treatment-related deaths were recorded, while procedure-related adverse events graded two or higher occurred in 10.5% of patients.
The study population consisted of patients with ECOG-PS 0-1, less than 70% liver involvement, and limited extrahepatic disease, reflecting appropriate selection criteria for PHP.
Delcath's HEPZATO KIT is FDA-approved in the United States as a liver-directed treatment for adults with metastatic uveal melanoma having unresectable hepatic metastases affecting less than 50% of the liver.
In Europe, the device-only configuration of the HDS is approved as CHEMOSAT and is used to treat various liver cancers through percutaneous hepatic perfusion procedures.